Objective: To explore the clinical efficacy of Nimodipine in the treatment of subarachnoid hemorrhage. Methods: 72 cases of patients with subarachnoid hemorrhage were randomly divided into treatment group (36 cases) and control group (36 cases), two groups was given routine sedation, hemostasis and Mannitol, based on the conventional treatment, the treatment group was used Nimodipine. Results: After 4 weeks of treatment, the efficiency of the treatment group had significantly higher compared with that of the control group (88.89％ vs 75.00％, ρ＜0.05), and GOS scores, the treatment group was significantly better than that of the control group. Common complications included rebleeding, cerebral vasospasm, hy-drocephalus in the two groups, but re—bleeding, cerebral vasospasm and hydrocephalus in the treatment group were significantly lower than those of the control group, and the mortality rate after treatment significantly lower than that of the control group, the differences were statistically significant in the two groups (ρ＜0.05). Conclusion: Nimodipine treatment of subarachnoid hemorrhage has good efficacy, and can be significantly improved GOS score, reduce the incidence of complications, should be popularized and applied.%目的:探讨尼莫地平治疗蛛网膜下腔出血的疗效.方法:将72例蛛网膜下腔出血患者随机分为治疗组和对照组,各36例,两组均给予常规镇静、止血及甘露醇治疗,治疗组在常规治疗的基础上加用尼莫地平.结果:经过4周治疗后,治疗组有效率(88.89%)明显高于对照组(75.00%)(P<0.05),且两组GOS评分比较,治疗组明显优于对照组.两组常见的并发症主要为再出血、脑血管痉挛、脑积水,其中治疗组的并发症再出血、脑血管痉挛及脑积水的发生率明显低于对照组,且治疗后死亡率也明显低于对照组,两组比较,差异均有统计学意义(P<0.05).结论:尼莫地平治疗蛛网膜下腔出血疗效好,可以明显改善GOS评分,降低并发症的发生率,值得临床推广和应用.
展开▼
